She Leads Biotech

She Leads Biotech

By Sharron CoxScienceLife Sciences
Download on the App Store

All She Leads Biotech episodes

  • S3 E25, Chaemin Lim - Chief Technology Officer of Coiled Therapeutics

    From Molecules to Machine Learning: CTO Chaemin Lim on Drug Design & Leadership.
    What does drug discovery look like in the age of AI?

    In this episode of She Leads Biotech, Sharron Cox sits down with Chaemin Lim, Chief Technology Officer of Coiled Therapeutics, for a wide-ranging discussion that spans synthetic chemistry, startup life, and the future of AI in oncology.

    With over 15 years in drug development, Chaemin shares how her love of chemistry began in her father’s lab in Korea and evolved into a career at the intersection of data, design, and deep science. From building AI tools for medicinal chemists to learning how to translate science for investors, her journey is anything but linear and all the more inspiring for it.


    In this episode:
    00:00 Intro
    02:30 Growing up in science (and her dad’s chemistry lab)
    05:45 Pharmacy school and falling in love with drug development
    10:40 Building her own computational chemistry lab in grad school
    17:30 From postdoc to industry: how AI came into play
    21:00 What AI can and can’t do in drug discovery
    26:30 Startup life and translating science to strategy
    29:00 Advice for women in biotech and defining yourself as a “designer”
    33:00 What’s next for Coiled Therapeutics

    Tune in for a thoughtful, practical, and occasionally hilarious conversation that proves science and leadership are anything but boring.

    #SheLeadsBiotech #ChaeminLim #CoiledTherapeutics #DrugDesign #AIInBiotech #WomenInSTEM #AuthenticLeadership #LifeSciences #BiotechLeadership #CNAInternationalUSA

    36 min
  • S3 E24, Carolyn Yeago Director of The Masters Program in Biomedical Innovation & Development- Advanced Therapeutics at Emory University

    In this episode of She Leads Biotech, I sit down with Carolyn Yeago, Director of the MS in Biomedical Innovation & Development – Advanced Therapeutics at Emory University.

    Carolyn’s career has taken her from being the first female co-op engineer at a med-tech company to shaping how the next generation of biotech leaders are trained — with a strong foundation in clinical, regulatory, and commercial strategy.

    We talk about:

    • Why early-stage biotech companies often skip critical operational knowledge

    • How academia and industry can work together more effectively

    • The importance of building teams who understand the why, not just the how

    • What’s happening in Atlanta’s growing biotech ecosystem

    • And how this new master’s program is filling the gaps most startups don’t even know they have

    If you’re hiring early-career talent or thinking about where your next pipeline of leadership will come from — this episode is for you.


    📌 Chapters / Timestamps

    00:00 – Meet Carolyn Yeago
    03:00 – From co-op engineer to biotech educator
    06:30 – The gaps she saw in early-stage teams
    09:30 – Building a program around the full product lifecycle
    13:30 – Regulatory awareness in the classroom
    17:00 – Collaborating with industry, founders, and faculty
    21:00 – What makes a student stand out in biotech
    24:00 – The rise of biotech in Atlanta
    27:00 – Final advice for future leaders


    🎓 Applications for the 2026 cohort are now open.

    🟣 This episode is sponsored by Phacilitate and Women in Advanced Therapies (WIAT).


    #SheLeadsBiotech #CarolynYeago #EmoryUniversity #AdvancedTherapeutics #BiotechEducation #WomenInSTEM #WorkforceDevelopment #AcademicInnovation #LifeSciences #CNAInternationalUSA

    45 min
  • S3 E23, Deanna Angello - Chief Commercial Officer

    In this episode of She Leads Biotech, I’m joined by Deanna Angello, a seasoned commercial leader whose career spans some of the biggest names in healthcare: Pfizer, Kite Pharma, J&J, and Genentech.

    But this isn’t just a highlight reel of commercial success. It’s a conversation about what happens when life interrupts the script — and how that moment can bring clarity, courage, and an entirely new sense of purpose.

    We talk about:

    • Navigating career grief after personal loss

    • How Genentech prepared her for some of the most high-stakes commercial threats in biotech

    • Why FDA approval is only the beginning — not the end — of access

    • Building scalable systems that serve both patients and teams

    • What she's looking for in her next chapter as a Chief Commercial Officer

    If you're building something big — and looking for someone who’s done it all but still thinks like a builder — you’ll want to hear this one.


    📌 Chapters / Timestamps

    00:00 – Meet Deanna Angello
    02:00 – From Pfizer to Genentech: early lessons and leadership
    06:00 – Grief, clarity, and stepping off the treadmill
    10:00 – Building commercial systems that last
    14:00 – Patient access and the real work after FDA approval
    18:30 – What she’s looking for in her next CCO role
    23:00 – Advice for leaders ready to rethink their own path


    #SheLeadsBiotech #DeannaAngello #BiotechLeadership #WomenInSTEM #ChiefCommercialOfficer #LifeSciences #PatientAccess #AuthenticLeadership #CareerPivot #CNAInternationalUSA

    48 min
  • S3 E22, Theresa Tribble - Entrepreneur & Life Sciences Leader

    In this episode of She Leads Biotech, Sharron Cox sits down with Theresa Tribble, a dynamic entrepreneur and life sciences leader whose career has taken her from health policy and MBA halls to some of the most innovative companies in biotech.

    Theresa has led strategy and growth at Everlywell, BigHat Biosciences, and Droplet Biosciences, and now she’s preparing to summit Mount Kilimanjaro as part of the 2026 Timmerman Traverse — raising $1M+ for early-career cancer researchers.

    This conversation is honest, bold, and full of insight for anyone navigating their own career pivots or seeking purpose in the path less traveled.


    We talk about:

    • Why she’s drawn to companies that “should already exist”

    • The difference between mentors and sponsors (and how to find both)

    • What made Everlywell the riskiest — and most rewarding — move

    • Leadership without a science background (and why it works)

    • The climb of a lifetime for cancer research

    • Her personal checklist for knowing when to say “yes” to an idea


    📌 Chapters / Timestamps

    00:00 – Meet Theresa Tribble
    02:00 – Her unexpected path into life sciences
    05:00 – Working at Everlywell: a bold career leap
    08:30 – Finding purpose in patient proximity
    11:00 – How she evaluates new ideas and career moves
    14:30 – Mentorship vs sponsorship
    18:00 – BigHat Biosciences and Droplet: different models, shared mission
    22:00 – Career pivot tips for people outside the lab
    25:00 – Timmerman Traverse: climbing Kilimanjaro for cancer research
    30:00 – Advice for building a career with meaning


    🎧 Tune in for a conversation that blends strategy, mission, and a whole lot of heart.

    39 min
  • S3 E21, Katja Betts, CEO of PROGEN

    In this episode of She Leads Biotech, Sharron Cox sits down with Katja Betts, CEO of PROGEN, one of Germany’s first biotech companies — now 40 years strong and still evolving.

    Katja’s leadership journey is anything but typical. From marketing to the boardroom, she now leads a 45-person team that partners globally with biotech giants like Thermo Fisher and Bio-Techne. But at the heart of it all? A deep commitment to precision, collaboration, and progress that lasts.

    They talk about:

    • PROGEN’s mission to make gene therapy tools more accessible and scalable

    • The leadership mindset Katja brought from brand strategy to biotech

    • Why innovation doesn’t have to be loud to be bold

    • Gender and generational bias in biotech leadership

    • How PROGEN is supporting clients around the world — without losing focus

    Whether you’re scaling a biotech company or building a career in life sciences, this episode offers a thoughtful, grounded take on leadership, growth, and impact.

    📌 Timestamps / Chapters
    00:00 – Meet Katja Betts & PROGEN’s history
    03:30 – From branding to biotech: Katja’s unconventional career path
    06:00 – What makes PROGEN different (and why clients stay 20+ years)
    09:00 – The mission: Making gene therapy better, together
    12:30 – Building tools that work without specialist equipment
    15:00 – Collaborating with Thermo Fisher, Bio-Techne, and more
    18:00 – Leadership in Germany: differences, networks, and gender dynamics
    22:00 – The weight of legacy and the power of steady progress
    25:00 – Advice for new leaders in biotech


    🎧 Listen now and share with someone building something with meaning.

    29 min
  • S3 E20, Jennifer Chain, The Leukopak Lady

    Jennifer Chain | The Leukopak Lady – Why Starting Materials Matter More Than You Think


    In this episode of She Leads Biotech, host Sharron Cox sits down with Jennifer Chain, immunologist, consultant, and founder of CSM Consulting, to explore a topic most people in biotech overlook, the strategic importance of starting materials in cell and gene therapy.

    Known on LinkedIn as The Leukopak Lady, Jennifer shares her journey from academia to entrepreneurship, her deep expertise in donor qualification, and why collection centers and therapy developers need to start thinking upstream if they want downstream success.

    Chapters:
    00:00 – Meet Jennifer Chain: From West Texas to starting materials expert
    03:00 – Why she chose gamma delta T cells over cancer research
    06:30 – Why donor selection is critical to manufacturing and clinical outcomes
    10:30 – What most execs misunderstand about leukopaks
    13:00 – How she built a consulting business (and the startup that didn’t work out)
    17:00 – The viral video series: “The Leukopak Lady” on LinkedIn & YouTube
    20:00 – The regulatory grey zones no one is talking about
    23:00 – Centralized vs decentralized manufacturing: hidden bottlenecks
    27:00 – Why donor stewardship is the new frontier in cell therapy
    30:00 – Her advice for early-career scientists breaking into the space


    Whether you're in CMC, clinical, regulatory, or BD — this episode will shift how you think about supply chains, success rates, and what it really means to build therapies that work.

    Listen now and follow Jennifer at #LeukopakLady for more insight.

    35 min
  • S3 E19, Susan Nichols CEO of Propel Biosciences

    Susan Nichols has spent her career bridging the gap between innovation and impact. Now, as CEO of Propel Biosciences, she’s helping startups in the cell and gene therapy space build commercial strategies that work, for patients, investors, and everyone in between.

    In this episode of #SheLeadsBiotech, Susan shares how her personal connection to rare disease shaped her path, what she learned transitioning from Big Pharma to biotech, and why commercialization isn’t just about revenue, it’s about responsibility.

    Chapters:
    00:00 – Meet Susan Nichols and her personal connection to rare disease
    03:00 – Why cell and gene therapy felt like “sci-fi” — and what made her believe
    06:30 – From Big Pharma to startup life: learning to lead without the handbook
    10:00 – The patient as north star: what keeps her going
    12:00 – Leadership vs. management: how her style evolved
    17:00 – Managing individuals, not job titles
    20:00 – Why mentoring isn’t about advice — it’s about curiosity
    22:30 – What Propel Biosciences does, and how she helps companies get market-ready
    26:00 – Why good science isn’t enough without a clear commercial pathway
    30:00 – Breaking through the noise: messaging, clarity, and value
    33:00 – Advice for those entering CGT (and what not to do)

    🎧 Tune in to hear from a powerhouse who’s seen every side of the industry — and is now paying it forward.


    42 min
  • S3 E18, Angela Vollstedt, Director of Global Cell & Gene Therapies Portfolio at Novartis

    In this episode of She Leads Biotech, Sharron Cox sits down with Angela Vollstedt, Director of Global Cell & Gene Therapies Portfolio at Novartis, for a conversation that blends operational grit with visionary thinking.

    Angela’s career spans two decades in pharma — from legacy manufacturing to advanced therapies — and she’s now at the forefront of shaping how personalized medicine can become scalable, accessible, and sustainable.

    We talk about:

    • Her unexpected start in a male-dominated manufacturing environment

    • The creative shift from operations to product development

    • Rethinking biotech leadership in uncharted territory

    • The “bus” model that could transform patient access in CGT

    • The mindset young biotech professionals need to succeed today

    Whether you’re scaling a CGT company or just starting out in life sciences, Angela’s story offers grounded insights and bold ideas about what it means to lead at the edge of innovation.


    Listen now and share with a leader navigating the new frontier of biotech.

    📌 Chapters / Timestamps:
    00:00 – Meet Angela Vollstedt
    01:00 – Her entry into pharma & manufacturing
    05:00 – Being one of the only women in the room
    07:00 – Lessons that shaped her leadership style
    11:00 – Transitioning into product development
    14:00 – Entering advanced therapies
    16:00 – Balancing excellence with innovation
    18:00 – A "bus" that could change patient access
    23:00 – Why patient awareness matters
    26:00 – What keeps her passionate about the work
    28:00 – Advice for the next generation of biotech leaders

    33 min
  • S3 E17, Jeanne Hecht, CEO & Chairwoman of Lexitas Pharma Services

    In this episode of She Leads Biotech, I sit down with Jeanne Hecht, CEO & Chairwoman of Lexitas Pharma Services, whose career spans global operations, clinical development, and private equity-backed growth — but whose leadership style is anything but cold and corporate.

    Jeanne gets real about the lessons she learned the hard way: the dangers of micromanagement, the beauty of asking for help, and why ego has no place in building something that lasts.

    We talk about:
    🔹 Her early career in clinical research and how she learned to “speak investor”
    🔹 Transitioning from doer to delegator — and how trust transformed her leadership
    🔹 The role of PE firms in shaping biotech strategy
    🔹 Her take on when founders should step back and bring in an operator
    🔹 What it means to lead with humility and consistency — especially as a woman in the C-suite

    💬 “A position of strength is when somebody understands they’re not in the right role — and they step aside so someone else can do it better.”

    📌 Chapters / Timestamps
    00:00 – Meet Jeanne Hecht
    02:30 – From clinical trials to the business side of biotech
    05:30 – The evolution of her leadership style: from micromanagement to mentorship
    08:45 – How her team helps her lead better
    11:00 – Building Lexitas with a people-first culture
    14:00 – What investors are really looking for in leadership
    17:00 – Advice for scientist-founders: when to step aside
    20:00 – Gender, confidence, and owning the room
    23:30 – Winning “CEO of the Year” on a chaotic morning
    27:00 – The biggest lesson she’s still learning
    30:00 – Her advice to women moving into executive roles

    🎧 A must-listen for biotech leaders at every stage — grounded, generous, and refreshingly real.

    #SheLeadsBiotech #JeanneHecht #LexitasPharma #WomenInLeadership #ClinicalDevelopment #PrivateEquity #BiotechLeadership #LifeSciences #CNAInternationalUSA


    39 min
  • S3 E16, Mini Manchanda, Senior Director of Precision Medicine at Kura Oncology

    In this episode of She Leads Biotech, Sharron Cox sits down with Mini Manchanda, Senior Director of Precision Medicine at Kura Oncology, to explore a career built on curiosity, compassion, and bold pivots.

    From her early research days in India to global biotech roles at Thermo Fisher, AstraZeneca, and now Kura, Mini shares how she’s helped shape the future of healthcare — one personalized solution at a time.

    We talk about:
    🔹 Redefining success after an early “failure”
    🔹 Working across diagnostics, drug development, and precision medicine
    🔹 Leading with intention in a high-growth biotech
    🔹 The difference between precision medicine and precision health
    🔹 Holistic care, Eastern medicine, and integrating new paradigms
    🔹 Mentorship, identity, and finding meaning beyond your job title

    “You don’t need to be hard to lead. You can lead with softness.”

    An honest and uplifting conversation with a scientist, strategist, and leader who’s building better systems — and lifting others as she rises.


    📌 Chapters / Timestamps
    00:00 – Meet Mini Manchanda
    02:00 – Childhood curiosity and falling in love with biology
    06:00 – When medical school didn’t work out — and why that was okay
    08:00 – The impact of constant relocation on resilience and adaptability
    10:00 – Getting into research and moving abroad for grad school
    12:00 – Transitioning from academia to industry
    14:00 – Thermo Fisher, Saudi genome projects, and diagnostics development
    16:00 – AstraZeneca and the global evolution of precision medicine
    19:00 – The power of purpose-driven leadership
    22:00 – What is precision medicine — and how is it evolving?
    24:00 – The future of precision health and data-informed wellness
    27:00 – Eastern vs. Western medicine: challenges and opportunities
    32:00 – Identity, purpose, and career ambitions
    34:00 – Advice for young women in science
    36:00 – Mentorship and paying it forward

    🎧 Listen now — and get inspired by a leader redefining what it means to do meaningful work in science and health.

    #SheLeadsBiotech #MiniManchanda #KuraOncology #PrecisionMedicine #WomenInSTEM #AuthenticLeadership #LifeSciences #BiotechInnovation #CareerGrowth #HolisticHealthcare

    43 min